In the matched cohort, the HBsAg‐positive group (n = 203) showed a higher risk of baseline liver cirrhosis (11.3% vs. 3.4%, p < 0.001) and initial hepatic dysfunction (10.8% vs. 5.4%, p = 0.005) as well as higher alanine transaminase, aspartate transaminase, and international normalized ratio levels than the HBsAg‐negative group (n = 812). The gene discussed is GPT; the disease is cirrhosis of liver.